RT Journal Article
SR Electronic
T1 Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267805
DO 10.1101/2021.12.15.21267805
A1 Doria-Rose, Nicole A.
A1 Shen, Xiaoying
A1 Schmidt, Stephen D
A1 O’Dell, Sijy
A1 McDanal, Charlene
A1 Feng, Wenhong
A1 Tong, Jin
A1 Eaton, Amanda
A1 Maglinao, Maha
A1 Tang, Haili
A1 Atmar, Robert L.
A1 Lyke, Kirsten E.
A1 Wang, Lingshu
A1 Zhang, Yi
A1 Gaudinski, Martin R
A1 Black, Walker P
A1 Gordon, Ingelise
A1 Guech, Mercy
A1 Ledgerwood, Julie E
A1 Misasi, John N
A1 Widge, Alicia
A1 Roberts, Paul C.
A1 Beigel, John
A1 Korber, Bette
A1 Pajon, Rolando
A1 Mascola, John R.
A1 Montefiori, David C.
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.15.21267805.abstract
AB The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in a pseudovirus assay in two different laboratories. Omicron was 49-84-fold less sensitive to neutralization than D614G and 5.3-6.2-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 µg mRNA-1273. A 50 µg boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.Competing Interest StatementM Maglinao and R Pajon are employees of Moderna, Inc.Funding StatementNIH 75N93019C00050 (DCM, XS), NIH U19 AI142790 (BK), Moderna, Inc., and Intramural Research Program of the Vaccine Research Center, NIAID, NIH (to NDR, SDS, SOD, YZ, MRG, WPB, IG, MG, JEL, and JRM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Duke University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors